Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating mutations in the epidermal growth factor receptor (EGFR) gene drive non-small-cell lung cancer (NSCLC) development.
• While exon 19 deletions and L858R substitutions are common, EGFR exon 20 insertions represent a distinct subset of activating mutations.
• These insertions confer resistance to standard EGFR tyrosine kinase inhibitors, historically limiting treatment options.

Purpose of the Study:

• To review the epidemiology, molecular characteristics, and tumor microenvironment of EGFR exon 20 insertion mutations in NSCLC.
• To summarize current and emerging systemic treatments, including targeted therapies and clinical trials.
• To discuss detection methods, resistance mechanisms, and future therapeutic directions for EGFR exon 20 insertion-driven NSCLC.

Main Methods:

• Literature review of epidemiological data, molecular structures, and treatment outcomes.
• Analysis of current therapeutic strategies, including targeted agents and chemotherapy.
• Examination of diagnostic techniques and emerging research on resistance.

Main Results:

• EGFR exon 20 insertions are the third most prevalent activating EGFR mutation, occurring in 4-10% of NSCLC cases.
• Amivantamab and mobocertinib are approved targeted therapies for patients progressing after chemotherapy.
• These newer agents represent a significant advancement over traditional chemotherapy for this patient population.

Conclusions:

• EGFR exon 20 insertion mutations present unique challenges in NSCLC treatment due to inherent resistance to prior EGFR inhibitors.
• The recent approval of targeted therapies marks a pivotal advancement, addressing a previously unmet clinical need.
• Ongoing research into resistance mechanisms and novel therapeutic strategies is crucial for improving outcomes in EGFR exon 20 insertion-driven NSCLC.